Kardiologie up2date, Table of Contents Kardiologie up2date 2016; 12(01): 21-23DOI: 10.1055/s-0041-108112 Hotline – Thrombozyten und Gerinnungssystem bei kardiovaskulären Erkrankungen © Georg Thieme Verlag KG Stuttgart · New York Direkte orale Antikoagulanzien – wichtige Unterschiede und Kerndaten M. Hubald , C. Mues , R. H. Strasser Recommend Article Abstract Buy Article All articles of this category Corrected by: Direkte orale Antikoagulanzien – wichtige Unterschiede und KerndatenKardiologie up2date 2016; 12(02): 130-130DOI: 10.1055/s-0042-108841 Abstract Direct oral anticoagulants (DOAC) are alternatives to vitamin K antagonists for prophylaxis of stroke in non-valvular atrial fibrillation and prophylaxis and therapy of venous thromboembolism. Currently there is a choice between the four DOACs Apixaban, Dabigatran, Edoxaban and Rivaroxaban. Strategies for differential therapy regarding indications, dosing, costs, drug interactions and cautions concerning impaired renal function are discussed briefly. Full Text References Literatur 1 EINSTEIN Investigators. Bauersachs R, Berkowitz SD, Brenner B et al. Oral rivaroxaban for symptomatic venous thromboembolism. N Engl J Med 2010; 363: 2499-2510 2 EINSTEIN–PE Investigators. Büller HR, Prins MH, Lensin AW et al. Oral rivaroxaban for the treatment of symptomatic pulmonary embolism. N Engl J Med 2012; 366: 1287-1297 3 AMPLIFY Investigators. Agnelli G, Buller HR, Cohen A et al. Oral apixaban for the treatment of acute venous thromboembolism. N Engl J Med 2013; 369: 799-808 4 RE-COVER Study Group. Schulman S, Kearon C, Kakkar AK et al. Dabigatran versus warfarin in the treatment of acute venous thromboembolism. N Engl J Med 2009; 361: 2342-2352 5 RE-COVER II Trial Investigators. Schulman S, Kakkar AK, Goldhaber SZ et al. Treatment of acute venous thromboembolism with dabigatran or warfarin and pooled analysis. Circulation 2014; 129: 764-772 6 Hokusai-VTE Investigators. Büller HR, Décousus H, Grosso MA et al. Edoxaban versus warfarin for the treatment of symptomatic venous thromboembolism. N Engl J Med 2013; 369: 1406-1415 7 ROCKET AF Investigators. Patel MR, Mahaffey KW, Garg J et al. Rivaroxaban versus warfarin in nonvalvular atrial fibrillation. N Engl J Med 2011; 365: 883-891 8 ARISTOTLE Committees and Investigators. Granger CB, Alexander JH, McMurray JJ et al. Apixaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2011; 365: 981-992 9 RE-LY Steering Committee and Investigators. Connolly SJ, Ezekowitz MD, Yusuf S et al. Dabigatran versus warfarin in patients with atrial fibrillation. N Engl J Med 2009; 361: 1139-1151 10 ENGAGE AF-TIMI 48 Investigators. Giugliano RP, Ruff CT, Braunwald E et al. Edoxaban versus warfarin in patients with atrial fibrillation. N Engl J Med 2013; 369: 2093-2104 11 Pollack CV Jr, Reilly PA, Eikelboom J et al. Idarucizumab for Dabigatran Reversal. N Engl J Med 2015; 373: 511-520
